[go: up one dir, main page]

WO1994003174A1 - Traitement d'infections dento-alveolaires avec la taurolidine et/ou le taurultam - Google Patents

Traitement d'infections dento-alveolaires avec la taurolidine et/ou le taurultam Download PDF

Info

Publication number
WO1994003174A1
WO1994003174A1 PCT/GB1993/001607 GB9301607W WO9403174A1 WO 1994003174 A1 WO1994003174 A1 WO 1994003174A1 GB 9301607 W GB9301607 W GB 9301607W WO 9403174 A1 WO9403174 A1 WO 9403174A1
Authority
WO
WIPO (PCT)
Prior art keywords
taurolidine
dental
taurultam
infection
infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1993/001607
Other languages
English (en)
Inventor
Rolf Wilhelm Pfirrmann
Peter Geistlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ed Geistlich Soehne AG fuer Chemische Industrie
Original Assignee
Ed Geistlich Soehne AG fuer Chemische Industrie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ed Geistlich Soehne AG fuer Chemische Industrie filed Critical Ed Geistlich Soehne AG fuer Chemische Industrie
Priority to EP93917947A priority Critical patent/EP0652753A1/fr
Priority to JP6505094A priority patent/JPH07509483A/ja
Priority to CA002141056A priority patent/CA2141056C/fr
Publication of WO1994003174A1 publication Critical patent/WO1994003174A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention is concerned with the combatting tooth and gum infections, in particular severe dental infections which are located within the alveolar region of the jaw.
  • the complex aetiology of oral infections results in the observation of widely variable resistance patterns following administration of conventional oral antibacterial preparations. Such preparations may also not be sufficiently active against some of the pathogenic organisms present. There is thus a need for a wide-spectrum agent to treat such mixed infections. Administration of an agent which is ineffective against some of the bacteria present will result in proliferation of the resistant bacterial species and complete elimination of the infection may not be achieved.
  • the types of bacteria present in dentoalveolar infections include aerobes such as Streptococcus viridans qr. , Streptococcus qr C. , Corynebacterium spp.. Neisseria spp and Haemophilus influenzae.
  • Anaerobes which are also commonly present include Peptococcus spp. , Bacteroides spp. and Furobacterium spp.
  • Conventional treatments include bactericidal agents such as chlorophenol-camphor-menthol, chlorhexidine and antibiotics such as chlorteracyclin and tetracinolon.
  • bactericidal agents such as chlorophenol-camphor-menthol, chlorhexidine and antibiotics such as chlorteracyclin and tetracinolon.
  • antibiotics such as chlorteracyclin and tetracinolon.
  • conventional agents require a relatively prolonged period of treatment to be completely effective.
  • Chlortetracycline and Democlocycline are considered inadvisable because of their instability and increased toxicity. It has been shown in this connection, that formation of the highly nephro-toxic anhydro-4-epitetracyclin-hydrochloride occurs in older Tetracycline preparations.
  • the aminoglycoside antibiotic Neomycin may only be applied locally because of its extreme nephrotoxic, ototoxic and muscle relaxant properties.
  • resorption can occur when the ectoderm is damaged (i.e. marginal and apical parodontitis, mucous-membrane ulceration) and repeated usage can lead to analogous side-effects.
  • the withdrawal of this preparation was suggested in 1975.
  • the quinoline derivative Aminoquinuride (Surfen) which increases the spectrum of Neomycin, has not been investigated sufficiently and its effectivity is controversial.
  • Synthetic corticosteroid derivatives like Prednisolone and Triamcinolone are intended to supercede the role of an analgesic in combination preparations. Although their strong anti-inflammatory and anti ⁇ allergic properties make for a quick reduction of pain this would always be accompanied by an immune separation which arises out of a comprehensive inhibition mesenchy al reaction. As well as an inhibition of the lympho-reticular system, damage also arises to the DNA- repair and mitosis capability which can lead to tissue atrophy. The fibrinogen concentration in the plasma is reduced by simultaneously strengthened fibrinolysis.
  • Chlorophenol-Ca phor and Chlorophenol- Camphor-Menthol solutions are often recommended for root canal instillation and no significantly higher or stronger pain sensation following instillation in the pulpen cavity has been reported as against comparative clinical experiments, the high toxic potential is undisputed. In animal experiments strong tissue toxic reactions have been observed in the form of inflammation and necrosis formation.
  • Chlorhexidine which has proved itself in extensive experimental and clinical studies as a broad spectrum anti-microbial, is also cell damaging. In tests carried out on human desmodontal fibroblasts, accelerated ageing and a cytopathological effect were demonstrated. The release of p-chloroaniline as a possible by-product of chlorohexidine, which is suspected of causing mutation and of being carcinogenic, is often denied.
  • taurolidine is effective against oral infections, especially those that are located within the infrastructure of the jaw, but exhibits a much reduced level of side-effects and provides effective relief in a shorter period.
  • taurolidine is a synthetic derivative of the naturally occurring 2-aminoethane sulphonic acid, taurine.
  • taurolidine is a potential anti ⁇ microbial substance, acting by a ethylol transfer mechanism, has been disclosed in GB 1,124,285. It is sold by Ed. Geistlich Sohne AG. under the registered Trade Mark 'Taurolin'.
  • the antibacterial substance taurultam is closely related to taurolidine and, indeed, is formed during the methylol transfer reaction between taurolidine and target substances. It is also produced by Ed. Geistlich Sohne AG. Taurultam is slightly more water soluble than taurolidine but possesses fewer methylol transfer groupings.
  • taurolidine compositions would be useful in combatting other, more severe dental infections such as gangrene, parodontitis and abscesses. Neither was it known that administration of a taurolidine composition was so much more effective as regards reducing the length of time and the dosage required for treatment.
  • the present invention provides the use of taurolidine and/or taurultam in the preparation of an orally acceptable medicament for combatting severe dental infections or dental infection following dental surgery.
  • the term "combatting” as used herein includes both therapeutic and prophylactic treatment.
  • severe dental infections is used herein to refer to those infections which have become established in the interior of the jaw infrastructure, eg. dentoalveolar infections, such as gangrene, parodontitis or dental abscesses.
  • parodontitis is an inflammatory reaction of the tissues surrounding a tooth and can be characterised by formation of periodontal pockets, pus formation, bone resorption, destruction of the periodontal ligament and tooth loss. Parodontitis is a different condition from parodontosis.
  • TNF tumour necrosis factor
  • taurolidine and/or taurultam can be used prophylactically following surgery such as implantation.
  • Dental, mandibular or maxillofacial surgery is relatively common and varies from a complete restructing of the jaw bone, (for example following injury to that area) to replacement of a natural tooth with an artificial dentiform implant (false tooth) .
  • Removal of a natural tooth may have occurred by accident, for example resulting from a blow to the face, or may be undertaken by surgical techniques made necessary by, for example, untreated decay of the tooth structure.
  • the tooth socket is generally prepared by the dental surgeon.
  • Usually a titanium implant is first located in the tooth socket, and then the false tooth proper is firmly attached to the titanium implant, conveniently by means of opposing screw threads so that the false tooth may be simply screwed into place.
  • taurolidine and/or taurultam can be used prophylactically, for example by simple local application, to greatly reduce the incidence of post-operative infection.
  • the present invention thus provides the use of taurolidine and/or taurultam in the preparation of an orally acceptable prophylactic medicament to prevent dental or gum infections, and in particular to prevent such infections following dental, andibular or maxillofacial surgery.
  • compositions of taurolidine and/or taurultam which may be used to combat severe dental infections (as defined above) or as a prophylaxis include gels, emulsions, liquid gel or rinse solutions.
  • compositions are new and comprise a further aspect of the present invention.
  • One particular formulation for use in combatting tooth infections is an aqueous emulsion comprising taurolidine or taurultam in solution in the aqueous phase.
  • the oily phase of such an emulsion can comprise a physiologically acceptable oil eg. a food -oil such as soya or arachis oil.
  • One or more emulsifiers can be present, for example non-ionic emulsifiers such as glyceryl monostearate, fatty alcohols such as cetyl or yristyl alcohol, or lecithin.
  • a thickening agent such as hydroxyethylcellulose (Natrosol 250 HHR) , carboxymethylcellulose, polyethylene glycol, sodium alginate, polyacrylic acid cross-linked by an alkyl ether of pentaerythritol or sucrose (Carbopol) or polyvinylpyrolidone is desirably added.
  • hydroxyethylcellulose Naatrosol 250 HHR
  • carboxymethylcellulose polyethylene glycol, sodium alginate
  • polyacrylic acid cross-linked by an alkyl ether of pentaerythritol or sucrose (Carbopol) or polyvinylpyrolidone is desirably added.
  • the advantage of such a formulation is delayed release of the taurolidine or taurultam when the formulation is introduced in the vicinity of the infection and resistance to elimination from the site of infection by saliva.
  • the present invention further provides an orally acceptable composition, said composition comprising taurolidine and/or taurultam together with pharmaceutically acceptable excipients in the form of a liquid gel, rinse solution or as an emulsion.
  • compositions according to the invention may be used either by themselves or in conjunction with surgery to combat the infection.
  • One particularly useful aspect is the impregnation of a gauze strip with a taurolidine and/or taurultam- containing emulsion which can be applied to the affected area by the dentist or orthodontist.
  • a taurolidine and/or taurultam containing gel is particular convenient for prophylactic use.
  • a tube of the gel can be given to the patient who will then apply it to the affected area, as required, for example up to 6 times a day, depending on the extent of surgery and the strength of the gel.
  • an orally acceptable composition according to the present invention will comprise 0.5 to 5% taurolidine by weight, preferably 1 to 3% by weight, or 0.75 to 7.5% by weight of taurultam, preferably 1.5 to 4.5%.
  • the invention further provides a method of combatting severe dental infections (as defined herein) , said method comprising administering an orally acceptable taurolidine and/or taurultam-containing composition to the affected area of the patient.
  • taurolidine and/or taurultam for combatting severe dental infections such as parodontitis, dental gangrene or abscesses and for the manufacture of dental compositions for such treatment.
  • the liquid compositions of the invention are particularly adapted for combatting dentoalveolar infections, such as gangrene or abscesses, for example by introduction via a syringe into tooth canals or application at or near the site of infection for delayed release.
  • dentoalveolar infections such as gangrene or abscesses
  • Such liquid compositions include emulsions, as indicated hereinafter, which may be applied via an impregnated gauze strip overlying the infected area, as well as rinse solution which can be used in the treatment of gangrene, abscesses and perikornitis and liquid dental gels which can be introduced via a syringe in the treatment of gangrene, apical astitis and root canal treatment.
  • Taurolidine has been tested for a number of orodental indications against therapy using conventional antibacterials. It could be seen that all target variables fell significantly more quickly under taurolidine medication than under conventional therapy. The total treatment time in the standard group was about 40% longer than in the taurolidine group. Moreover significantly less antibiotics and analgetics were required under taurolidine medication than under standard therapy. In contrast to most of the conventional preparations, which implicate a lot of side effects as irritation of smell and taste, discoloring of teeth and fillings, allergic reactions and histotoxicity with consecutive necroses, taurolidine only -shows slight pain for some minutes after application during the acute period of inflammation. The following study clearly demonstrates that treatment of severe dental infections using taurolidine compositions results in a marked decrease in the length of treatment time.
  • test substances investigated were 4 different galenic presentation forms of the active component taurolidine and 4 conventional finished pharmaceuticals.
  • AUREOMYCIN" ointment 3% (Cynamid-Novalis, Wolfratschausen/FRG) (1 g cont.: 30 mg chlorotetracycline, vaseline-anhydrous lanolin)
  • DONTISOLON ointment Type M (Hoechst, Frankfurt Germany) (1 g cont.: 5 mg prednisolone, 2 mg neomycin HCL, 3 mg aminoquinuride 2HC1 3.5 H 2 0, excipients)
  • Tables 1 and 2 show the antimicrobial therapy regimens defined for patient groups A (Taurolidine group) and B (Standard group) . It is evident, that the only difference, with the same quantity of substance applied in the same form, v/as the choice of " preparation.
  • T represents "Taurolin" in the Table above.
  • the score-level 5 (total) was given at the moment of complete remission and describes consequently the final point of treatment.
  • Tables 4 and 5 show the course of the remission for the two therapy regimens.
  • a superior effectiveness of taurolidine to the standard therapy was demonstrable for all 6 indications corresponding to a clinical relevant more rapid recovery (p ⁇ 0.0001).
  • the standard deviations in the taurolidine group were generally smaller than the comparable values in the standard group. This is also a fact that allows the dentist a better estimation of the required treatment time. Any influence of the investigated modifying variables as age, sex, localisation of the lesion and optional antibiotic or analgetic administration on the process of recovery as well as on total treatment time could not be shown neither in the taurolidine nor in the standard group.
  • TIME (days) TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD
  • TIME (days) TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD TAUR. STANDARD
  • Composition % (by weight)
  • Composition % (by weight)
  • Composition % (by weight)
  • Composition % (by weight)
  • Composition % (by weight)
  • B add to A/C and homogenise. Heat to 70°C; D mix with heating to 70°C; add the fatty phase to the aqueous phase in an emulsifying device and emulsify; cool with stirring to 25°C;
  • Composition % (by weight)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)

Abstract

La présente invention fournit un nouveau moyen pour combattre les infections dento-alvéolaires graves telles que la gangrène des dents, la parodontite et les abcès, qui fait appel à l'administration des agents de transfert du méthylol que sont la taurolidine et/ou le taurultam. Dans une forme d'exécution, les compositions de taurolidine et/ou de taurultam peuvent être administrées à titre prophylactique pour combattre une infection postopératoire. Certaines nouvelles compositions comprenant la taurolidine et/ou le taurultam sont également décrites.
PCT/GB1993/001607 1992-07-30 1993-07-29 Traitement d'infections dento-alveolaires avec la taurolidine et/ou le taurultam Ceased WO1994003174A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP93917947A EP0652753A1 (fr) 1992-07-30 1993-07-29 Traitement d'infections dento-alveolaires avec la taurolidine et/ou le taurultam
JP6505094A JPH07509483A (ja) 1992-07-30 1993-07-29 歯と歯槽の感染の処置
CA002141056A CA2141056C (fr) 1992-07-30 1993-07-29 Traitement contre les infections dentoalveolaires au moyen de taurolidine et (ou) de taurultam

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9216155.3 1992-07-30
GB929216155A GB9216155D0 (en) 1992-07-30 1992-07-30 Treatment of dentoalveolar infections

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US77012796A Continuation 1992-07-30 1996-12-19

Publications (1)

Publication Number Publication Date
WO1994003174A1 true WO1994003174A1 (fr) 1994-02-17

Family

ID=10719520

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1993/001607 Ceased WO1994003174A1 (fr) 1992-07-30 1993-07-29 Traitement d'infections dento-alveolaires avec la taurolidine et/ou le taurultam

Country Status (5)

Country Link
EP (1) EP0652753A1 (fr)
JP (1) JPH07509483A (fr)
CA (1) CA2141056C (fr)
GB (1) GB9216155D0 (fr)
WO (1) WO1994003174A1 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
WO2000001391A1 (fr) * 1998-07-02 2000-01-13 Biolink Corporation Verrous antimicrobiens comprenant des derives de la taurinamide et d'acides carboxyliques et/ou leurs sels
JP2000501729A (ja) * 1995-12-12 2000-02-15 オメロス メディカル システムズ，インコーポレーテッド 疼痛、炎症、けいれんおよび再狭窄の抑制のための血管灌注溶液並びにその方法
WO2001039762A3 (fr) * 1999-12-06 2002-05-02 Rhode Island Hosp Lifespan Ptr Methodes de traitement de tumeurs
EP0928187A4 (fr) * 1996-06-24 2002-10-02 Bio Safe Entpr Inc Composition antibacterienne
US6753328B2 (en) 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases
WO2004058193A1 (fr) * 2002-12-20 2004-07-15 3M Espe Ag Materiau dentaire contenant des substances bacteriostatiques et/ou bactericides
EP1442753A1 (fr) * 2003-02-03 2004-08-04 Polaschegg, Hans-Dietrich, Dr.techn. Composition pour la prévention des infections par prothèses endovasculaires
JP2007031454A (ja) * 1994-12-12 2007-02-08 Omeros Corp 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US7479505B2 (en) 1999-12-06 2009-01-20 Geistlich Phama Ag Use of taurolidine to treat tumors
EP1797884A3 (fr) * 1999-12-06 2010-02-10 Geistlich Pharma AG Utilisation de taurolidine ou de taurultame pour la manufacture d'un médicament pour le traitement des tumeurs du système nerveux central
WO2012042349A1 (fr) * 2010-09-27 2012-04-05 Geistlich Pharma Ag Préparation de soins dentaires antimicrobienne
US8933147B2 (en) 2005-11-17 2015-01-13 3M Innovative Properties Company Anti-microbial dental impression material
US9339036B2 (en) 2004-11-02 2016-05-17 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
WO2005115357A2 (fr) * 2004-05-14 2005-12-08 Hans-Dietrich Polaschegg Formulations de taurolidine et administration: traitements thérapeutiques et protection antimicrobienne contre la formation de biofilm bactérien
CN108430476A (zh) * 2015-10-07 2018-08-21 科医公司 牛磺罗定的皮肤渗透制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2618666A1 (de) * 1975-04-28 1976-11-18 Gaba Ag Neuartige mund- und zahnpflegemittel
GB1557163A (en) * 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
EP0139534A2 (fr) * 1983-10-20 1985-05-02 Ed. Geistlich Söhne Ag Für Chemische Industrie Compositions pour le traitement prophylactiques de l'ostéite et de l'ostéomyélite
EP0521225A1 (fr) * 1991-07-04 1993-01-07 Hawe Neos Dental Dr. H. v. Weissenfluh SA Compositions pharmaceutiques pour le traitement de la parodontose, contenant l'acide clavulanique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2618666A1 (de) * 1975-04-28 1976-11-18 Gaba Ag Neuartige mund- und zahnpflegemittel
GB1557163A (en) * 1975-06-24 1979-12-05 Geistlich Soehne Ag Dental care preparations
EP0139534A2 (fr) * 1983-10-20 1985-05-02 Ed. Geistlich Söhne Ag Für Chemische Industrie Compositions pour le traitement prophylactiques de l'ostéite et de l'ostéomyélite
EP0521225A1 (fr) * 1991-07-04 1993-01-07 Hawe Neos Dental Dr. H. v. Weissenfluh SA Compositions pharmaceutiques pour le traitement de la parodontose, contenant l'acide clavulanique

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ARZNEIMITTELFORSCHUNG vol. 42, no. 9, September 1992, pages 1157 - 1159 M. ZIMMERMANN ET AL. 'In vitro activity of taurolidine, chlorophenol-camphor-menthol and chlorhexidine against oral pathogenic microorganisms' *
CLIN PREV DENT vol. 13, no. 2, 1991, pages 13 - 22 REYNOLDS ET AL. 'Taurolin as an oral rinse I. Antimicrobial effects in vitro and in vivo.' *
ED. BR]CKNER 'Taurolin-ein neues Konzept zur antimikrobiellen Chemotherapie chirurgischer Infektion; Chapter 43' 1985 cited in the application *
FORTSCHR. KIEFER GESICHTSCHIR. vol. 30, 1985, pages 35 - 37 G.H. NENTWIG ET AL. 'Zur Behandlung postchirurgischer Knocheninfektionen' *
G.H. NENTWIG ET AL.: 'Erste klinische Erfahrungen mit Taurolin-Feingranulat in der zahn{rztlichen Chirurgie' *
INT. J. CLIN. PHARMACOL. THER. TOXICOL. vol. 31, no. 3, March 1993, pages 130 - 136 M. ZIMMERMANN ET AL. 'The antimicrobial actions of taurolin and other preparations on the pathogenic spectrum in dentoalveolar infections' *

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10510540A (ja) * 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
JP2012184274A (ja) * 1994-12-12 2012-09-27 Omeros Corp 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
JP2009024022A (ja) * 1994-12-12 2009-02-05 Omeros Corp 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
JP2007031454A (ja) * 1994-12-12 2007-02-08 Omeros Corp 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
JP2000501729A (ja) * 1995-12-12 2000-02-15 オメロス メディカル システムズ，インコーポレーテッド 疼痛、炎症、けいれんおよび再狭窄の抑制のための血管灌注溶液並びにその方法
JP2008094855A (ja) * 1995-12-12 2008-04-24 Omeros Corp 疼痛、炎症、けいれんおよび再狭窄の抑制のための血管灌注溶液並びにその方法
EP0928187A4 (fr) * 1996-06-24 2002-10-02 Bio Safe Entpr Inc Composition antibacterienne
WO2000001391A1 (fr) * 1998-07-02 2000-01-13 Biolink Corporation Verrous antimicrobiens comprenant des derives de la taurinamide et d'acides carboxyliques et/ou leurs sels
US6995164B2 (en) 1999-12-06 2006-02-07 Rhode Island Hospital Methods of treating tumors
WO2001039763A3 (fr) * 1999-12-06 2002-07-11 Rhode Island Hosp Lifespan Ptr Utilisation de composes renfermant du methylol pour traiter des tumeurs
WO2001039762A3 (fr) * 1999-12-06 2002-05-02 Rhode Island Hosp Lifespan Ptr Methodes de traitement de tumeurs
US6964959B2 (en) 1999-12-06 2005-11-15 Carter Wallace, Inc. Use of a methylol-containing compound to treat tumors
EP2332542A3 (fr) * 1999-12-06 2011-09-28 Geistlich Pharma AG Utilisation de composes renfermant du methylol pour la fabrication d'un medicament pour traiter des tumeurs
AU784538B2 (en) * 1999-12-06 2006-04-27 Geistlich Pharma Ag Use of methylol-containing compounds to treat tumors
US6521616B2 (en) 1999-12-06 2003-02-18 Rhode Island Hospital, A Lifespan Partner Methods of treating tumors with taurolidine
US6429224B1 (en) 1999-12-06 2002-08-06 Rhode Island Hospital, A Lifespan Partner Use of taurolidine to treat tumors
US7479505B2 (en) 1999-12-06 2009-01-20 Geistlich Phama Ag Use of taurolidine to treat tumors
EP1797884A3 (fr) * 1999-12-06 2010-02-10 Geistlich Pharma AG Utilisation de taurolidine ou de taurultame pour la manufacture d'un médicament pour le traitement des tumeurs du système nerveux central
US6753328B2 (en) 2001-10-01 2004-06-22 Rhode Island Hospital Methods of inhibiting metastases
WO2004058193A1 (fr) * 2002-12-20 2004-07-15 3M Espe Ag Materiau dentaire contenant des substances bacteriostatiques et/ou bactericides
EP1442753A1 (fr) * 2003-02-03 2004-08-04 Polaschegg, Hans-Dietrich, Dr.techn. Composition pour la prévention des infections par prothèses endovasculaires
US9339036B2 (en) 2004-11-02 2016-05-17 Nd Partners, Llc Antimicrobial locking solutions comprising taurinamide derivatives and biologically acceptable salts and acids, with the addition of small concentrations of heparin
US8933147B2 (en) 2005-11-17 2015-01-13 3M Innovative Properties Company Anti-microbial dental impression material
WO2012042349A1 (fr) * 2010-09-27 2012-04-05 Geistlich Pharma Ag Préparation de soins dentaires antimicrobienne
US8852617B2 (en) 2010-09-27 2014-10-07 Geistlich Pharma Ag Antimicrobial dental care preparation
AU2011309832B2 (en) * 2010-09-27 2015-01-15 Geistlich Pharma Ag Antimicrobial dental care preparation
US11738120B1 (en) 2022-04-14 2023-08-29 Cormedix Inc. Synthesis of taurolidine, purity profiles and polymorphs

Also Published As

Publication number Publication date
CA2141056A1 (fr) 1994-02-17
JPH07509483A (ja) 1995-10-19
CA2141056C (fr) 2005-02-15
EP0652753A1 (fr) 1995-05-17
GB9216155D0 (en) 1992-09-09

Similar Documents

Publication Publication Date Title
CA2141056C (fr) Traitement contre les infections dentoalveolaires au moyen de taurolidine et (ou) de taurultam
AU716540B2 (en) New pharmaceutical composition with anaesthetic effect
KR101337578B1 (ko) 의료 장치 및 의약 제형에 유용한 점막 접착성 자일로글루칸 함유 제형
JP2022164947A (ja) 高張性抗微生物治療用組成物
CN110996891B (zh) 包含氯己定的凝胶
EP0404558A1 (fr) Composition de polymère liquide et méthode d'utilisation
US5902110A (en) Bone regeneration
PL209943B1 (pl) Zastosowanie moksifloksacyny stanowiącej kwas 1-cyklopropylo-6-fluoro-1,4-dihydro-8-metoksy-7-[(4aS,7aS)-oktahydro-6H-pirolo [3,4-b]pirydyn-6-ylo]-4-okso-3-chinolino-karboksylowy
US6488912B1 (en) Treatment of dentoalveolar infections with taurolidine and/or taurultam
AT15430U1 (de) Dentales Mittel auf Basis von Hyaluronan und Octenidindihydrochlorid
FR2618670A1 (fr) Preparation medicamenteuse a base d'huiles essentielles, ainsi que pate dentaire et gomme a macher la contenant
Alpan et al. Ozone in dentistry
Nariman et al. Clinical efficacy of hyaluronic acid in post-extraction sockets of impacted mandibular third molar
EP3914258B1 (fr) Composition pour le traitement de la parodontite et la régénération de la papille interdentaire
US20140303101A1 (en) Compositions for dental care
RU2809005C1 (ru) Средство для ухода за полостью рта, содержащее гексапептид и хлоргексидин
US12485175B2 (en) Hypertonic antimicrobial therapeutic compositions
RU2330645C2 (ru) Способ лечения пародонтита
JP2895343B2 (ja) 咬合性外傷の治療剤
JPS62273910A (ja) 口腔用組成物
RU2761303C1 (ru) Способ получения фармацевтической композиции и фармацевтическая композиция для лечения и профилактики заболеваний пародонта
UA125272C2 (uk) Засіб у формі гелевої композиції "бензидафлазівердин" з пролонгованою дією для лікування захворювань тканин пародонта
JPH0764732B2 (ja) 歯痛、歯髄炎治療剤
MXPA97009941A (en) New pharmaceutical composition with anesthesia effect

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2141056

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993917947

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 374722

Country of ref document: US

Date of ref document: 19950215

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1993917947

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1993917947

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1993917947

Country of ref document: EP